RFP ANNOUNCEMENT: Clinical Site and Study Monitoring, RFP-NIAID-DAIDS-NIHAI2008045

Notice Number: NOT-AI-09-009

Key Dates
Release Date: November 4, 2008
Receipt Date: April 7, 2009

RFP will be available electronically on/about December 8, 2008, and may be accessed through FedBizOpps http://www.fedbizopps.gov/.

Issued by
National Institutes of Health (NIH), (http://www.nih.gov)

Description

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases.  The NIAID, Division of AIDS, as the Investigational New Drug (IND) Application sponsor for a large number of DAIDS-funded clinical trials, has a requirement to monitor clinical trials to ensure compliance with DAIDS, domestic and country-specific regulatory requirements and guidelines, verify the accuracy and completeness of clinical trial data, and assess adherence to protocol-specific requirements.  The NIAID, Division of AIDS, is seeking a contractor to provide comprehensive clinical site and study monitoring services for the NIAID/DAIDS extramural clinical trial research portfolio.  The scope of activities to be performed includes:

  1. site initiation visits prior to clinical trial implementation to ensure compliance with DAIDS, U.S. and, where appropriate, country-specific regulatory requirements and guidelines.
  2. routine site monitoring visits for active clinical trials to ensure compliance with DAIDS, U.S. and, where appropriate, country-specific regulatory requirements and guidelines, verify the accuracy and completeness of clinical trial data, and assess adherence to protocol-specific requirements.
  3. specialized site monitoring visits for a variety of purposes, including regulatory audits, assessments of overall and protocol-specific research pharmacy operations and management of investigational products, and remedial or for cause site visits to implement and ensure adherence to corrective actions required to address site or study deficiencies identified through routine site monitoring.
  4. site closeout visits to ensure appropriate completion of clinical trials, storage of clinical records and disposition of investigational products.
  5. preparation of written reports of all site monitoring visits, including identification of problems and deficiencies and recommendations for remedial actions.
  6. the development and implementation of Standard Operating Procedures for the conduct of clinical site and study monitoring functions, including the components to be reviewed/assessed and the processes to be used for each type of site visit.
  7. the development and implementation of a training plan for site monitors on staff and new hires and for evaluating the effectiveness and efficiency of training activities conducted.
  8. collaboration and coordination of clinical site and study monitoring activities and data generated through these activities with multiple other NIAID/DAIDS clinical research support contractors and HIV/AIDS Clinical Trials Network components.
  9. the development and implementation of a Quality Assurance/Quality Control (QA/QC) Plan to ensure the efficient and effective performance of monitoring functions and the appropriate management of the project.

It is anticipated that one cost reimbursement, completion type contract will be awarded for a seven-year period of performance beginning on or about December 4, 2009.  In addition to the above functions and services to be provided for the Base Period, up to four Options for expanded services under the contract may be exercised at the discretion of the Government.  These Options include staffing, management, oversight and additional facilities and equipment required for:

Option 1 – Clinical Site and Study Monitoring for a Phase IIb/III Vaccine Clinical Trial

Option 2 – Clinical Site and Study Monitoring for a Phase IIb/III Microbicide Trial

Option 3 – Clinical Site and Study Monitoring for Phase IIa Vaccine Clinical Trials

Option 4 – Clinical Site and Study Monitoring for Phase IIa Microbicide Clinical Trials

Estimated Staffing requirements
                                    
It is estimated that the provision of FTEs will be approximately as follows:

THE NAICS Code is 541712 with a size standard of 500 employees.  All responsible sources may submit a proposal which will be considered by the Agency. This notice does not commit the Government to award a contract.  No collect calls will be accepted.  No facsimile or email transmissions will be accepted.

Inquiries

For questions or further information, contact:

Michael Finn, Contract Specialist
Office of Acquisitions, DEA, NIAID, NIH, DHHS
6700-B Rockledge Drive, Room 3105
Phone: 301-496-0612
Fax: 301-480-4675
finnm@niaid.nih.gov

Eileen Webster-Cissel, Contracting Officer
Office of Acquisitions, DEA, NIAID, NIH, DHHS
6700-B Rockledge Drive, Room 3151
Phone: 301-496-0612
Fax: 301-480-4675
webstere@niaid.nih.gov

 


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.